Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Article Page

Abstract

Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.

Keywords: bispecific, immunotherapy, multiple myeloma, non-Hodgkin’s lymphoma.

Citation: Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma. Drugs Context. 2021;10:2021-2-4. https://doi.org/10.7573/dic.2021-2-4

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: JCC Consultancy: AbbVie, MorphoSys, Kite/Gilead, Novartis, Karyopharm, Bayer; Speaker Bureau: AstraZeneca, Epizyme, Genentech, MorphoSys. OCP: No conflict of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/08/dic.2021-2-4-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Castaneda-Puglianini O, Chavez JC. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Castaneda-Puglianini O, Chavez JC. https://doi.org/10.7573/dic.2021-2-4. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/bispecific-antibodies-for-non-hodgkins-lymphomas-and-multiple-myeloma

Correspondence: Julio Chavez, Department of Malignant Hematology, Moffit Cancer Center, 12902 Magnolia Drive FOB, Tampa, FL 33612, USA. Email: julio.c.chavez@moffitt.org

Provenance: Invited; externally peer reviewed.

Submitted: 19 February 2021; Accepted: 13 August 2021; Publication date: 21 September 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF